Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

The standard treatment for diffuse large B cell lymphoma (DLBCL) is rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine (VCR), and prednisone). Maintaining high dose intensity of cytotoxic treatment has been associated with better outcome but little is known about the role of maintaining...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Hematol
Asıl Yazarlar: Mörth, Charlott, Valachis, Antonios, Sabaa, Amal Abu, Molin, Daniel, Flogegård, Max, Enblad, Gunilla
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2018
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182738/
https://ncbi.nlm.nih.gov/pubmed/30091025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-018-3437-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller